Currently, immunohistochemical panel is used for decisions regarding all breast cancer therapy, since, in addition to being prognostic, it has predictive value for endocrine therapy, anti-HER2 therapy, chemotherapy and immunotherapy.22, 23. The gene discussed is ERBB2; the disease is breast carcinoma.